An Oxford University study reports that the incidence of a rare clotting complication, cerebral venous sinus thrombosis (CVST or CVT), is significantly higher with COVID-19 infection compared to after COVID-19 vaccination (Taquet et al. OSF preprint, 14 April 2021; https://osf.io/a9jdq/). The study has not been peer reviewed. Read More
Latest News
Are trial data generalizable to MS population?
April 27, 2021An analysis of patients in the German MS Register has found that 83% of real-world patients would not have met inclusion/exclusion criteria for entry in a trial of disease-modifying therapies (Jalusic et al. Mult Scler 2021; epublished January 20, 2021). Read More
COVID variants: is one dose better than nothing?
April 26, 2021Few vaccine responders with fingolimod, ocrelizumab
April 23, 2021Most MS patients currently treated with fingolimod or ocrelizumab will fail to mount an immune response to COVID-19 vaccination, according to the results of the first real-world study of vaccine response in MS patients on disease-modifying therapies (DMT) (Achiron et al. Ther Adv Neurol Disord 2021:14:1-8). An adequate vaccine response was seen in cladribine-treated patients. Read More